Puma Biotechnology Inc (NAS:PBYI)
$ 4.94 -0.195 (-3.8%) Market Cap: 238.30 Mil Enterprise Value: 251.28 Mil PE Ratio: 15.44 PB Ratio: 4.66 GF Score: 59/100

Puma Biotechnology Inc to Discuss the Alisertib Licensing Agreement Call Transcript

Sep 20, 2022 / 09:00PM GMT
Release Date Price: $2.49 (+5.96%)
Operator

Good afternoon. My name is Diego, and I will be your conference call operator today. (Operator Instructions) As a reminder, this call is being recorded. I would now like to turn the conference call over to Mariann Ohanesian, Senior Director of IR for Puma Biotechnology. You may begin your conference.

Mariann Ohanesian
Puma Biotechnology, Inc. - Senior Director of IR

Thank you, Diego. Good afternoon, and welcome to Puma's conference call to discuss our exclusive license agreement with Takeda for the development and commercialization of alisertib, an investigational aurora kinase A inhibitor. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President and Chairman of the Board of Puma Biotechnology; and Dr. Alvin Wong, Chief Scientific Officer.

As a reminder, this call is also being webcast. The webcast will be archived on our website and available for replay for the next 90 days.

Before I turn the call over to Alan, I would like to note that during this conference call, we will make forward-looking statements within the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot